NewLimit: Funding, Investors & Team (Oct 2026)
NewLimit is a biotechnology company dedicated to significantly increasing human healthspan. We are working on creating medications that target age-related illnesses by reprogramming the epigenome, a novel approach to rejuvenating aged and diseased cells. Our research involves utilizing functional genomics, pooled perturbation screening, and machine learning algorithms to better understand the relationship between epigenetic aging and disease through large-scale experiments.
NewLimit has raised $650M across 4 funding rounds on record, the most recent a Series C of $435M announced in Jun 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NewLimit Company Profile and Key Stats
Latest funding round on record: Jun 2026.
NewLimit Funding Rounds
NewLimit raised $40.0M in a Series A announced in May 2023.
2 years later, a Series B of $130M was announced in May 2025.
5 months later, an undisclosed round of $45.0M was announced in Oct 2025.
8 months later, a Series C of $435M was announced in Jun 2026.
NewLimit Founders and Leadership Team
Contact details for the NewLimit team: 1 of 2 have an email address on file.
Start 14-day free trial →NewLimit Funding Compared to Other Biotechnology Startups
NewLimit's latest round of $435M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NewLimit in Biotechnology and South San Francisco
Companies Similar to NewLimit
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
NewLimit Funding FAQs
What does NewLimit do?
NewLimit is a biotechnology company dedicated to significantly increasing human healthspan. We are working on creating medications that target age-related illnesses by reprogramming the epigenome, a novel approach to rejuvenating aged and diseased cells. Our research involves utilizing functional genomics, pooled perturbation screening, and machine learning algorithms to better understand the relationship between epigenetic aging and disease through large-scale experiments.
How much funding has NewLimit raised?
NewLimit has raised $650M across 4 rounds on record. The most recent is a Series C of $435M announced in Jun 2026.
When did NewLimit last raise funding?
NewLimit's most recent funding round on record is a Series C of $435M, announced in Jun 2026.
Who founded NewLimit?
FundedIQ lists Greg Johnson (Founder), Jacob Kimmel (Founder) at NewLimit.
Where is NewLimit headquartered?
NewLimit is based in South San Francisco, California, United States.
How many employees does NewLimit have?
NewLimit is in the 11-50 employee band.
How does NewLimit's funding compare to other Biotechnology startups?
NewLimit's latest round of $435M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's NewLimit Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NewLimit is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.